Neuregulin 1: an intriguing therapeutic target for neurodevelopmental disorders

Area of Science:

• Neuroscience
• Psychiatry
• Molecular Biology

Background:

• Neurodevelopmental disorders, including schizophrenia (Sz) and attention deficit hyperactivity disorder (ADHD), impose significant burdens.
• Neuregulin 1 (NRG1) and its receptor ErbB4 are implicated in regulating neural circuits crucial for cognitive functions.

Purpose of the Study:

• To examine the potential of modulating NRG1-ErbB4 signaling for therapeutic intervention in neurodevelopmental disorders.
• To explore cell type and brain region-specific targeting of the NRG1 system.

Main Methods:

• Review of emerging research on NRG1-ErbB4 signaling pathways.
• Examination of effects on fast-spiking parvalbumin positive (PV+) and vasoactive intestinal peptide positive (VIP+) interneurons.
• Proposal for preclinical studies in the prefrontal cortex (PFC).

Main Results:

• Decreasing NRG1-ErbB4 signaling in PV+ interneurons may reactivate cortical plasticity.
• Increasing NRG1-ErbB4 signaling in VIP+ interneurons may also promote plasticity.
• These modulations suggest potential therapeutic avenues for cognitive deficits.

Conclusions:

• Targeting NRG1-ErbB4 signaling in specific interneuron populations presents a novel strategy for neurodevelopmental disorders.
• Further preclinical research is needed to validate these findings and address challenges in cell-type specific gene therapy.